bioAffinity Technologies (BIAF) Income from Continuing Operations (2021 - 2026)
bioAffinity Technologies (BIAF) posted quarterly Income from Continuing Operations of 3630610.0 for Q1 2026, down 36.47% year-over-year from 5714589.64 in Q1 2025, and down 15.72% quarter-over-quarter from 3137466.0 in Q4 2025.
bioAffinity Technologies (BIAF) Income from Continuing Operations (2021 - 2026) Analysis & Trends
bioAffinity Technologies (BIAF) has reported Income from Continuing Operations for 6 consecutive years, with 3630610.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 36.47% year-over-year to 3630610.0; the TTM figure through Mar 2026 stood at 15879947.0 (down 63.06% YoY), while the FY2025 annual figure was 14909754.0, down 64.93% from the prior year.
- Income from Continuing Operations retreated to 3630610.0 in Q1 2026 per BIAF's latest filing, from 3137466.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 88052.0 in Q2 2022 and bottomed at 5051084.0 in Q3 2025.
- Historically, Income from Continuing Operations has averaged 2568901.12 across 5 years, with a median of 2290884.0 in 2023.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations soared 69.97% — and 2023, when it slumped 1876.3%.
- bioAffinity Technologies' Income from Continuing Operations stood at 1674583.0 in 2022, then tumbled by 41.72% to 2373164.0 in 2023, then retreated by 25.02% to 2966897.0 in 2024, then retreated by 5.75% to 3137466.0 in 2025, then slipped by 15.72% to 3630610.0 in 2026.
- Business Quant data shows BIAF's Income from Continuing Operations at 3630610.0 in Q1 2026, 3137466.0 in Q4 2025, and 5051084.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn | 1.76 Bn |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn | 870.00 Mn |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn | -66.93 Mn |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn | 339.00 Mn |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn | 241.00 Mn |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn | 338.41 Mn |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn | 207.00 Mn |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn | 232.90 Mn |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn | 299.10 Mn |
| 10 | bioAffinity Technologies | 1.78 Mn | -649,139.45 | - | -3.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.37 Mn |
| Mar 31, 2026 | -3.63 Mn |
| Dec 31, 2025 | 29.80 Mn |
| Sep 30, 2025 | -5.05 Mn |
| Jun 30, 2025 | -4.06 Mn |
| Mar 31, 2025 | -2.66 Mn |
| Dec 31, 2024 | -1.06 Mn |
| Sep 30, 2024 | -2.00 Mn |
| Jun 30, 2024 | -2.11 Mn |
| Mar 31, 2024 | -1.96 Mn |
| Dec 31, 2023 | -2.37 Mn |
| Sep 30, 2023 | -2.29 Mn |
| Jun 30, 2023 | -1.74 Mn |
| Mar 31, 2023 | -1.53 Mn |
| Dec 31, 2022 | -1.67 Mn |
| Sep 30, 2022 | -4.92 Mn |
| Jun 30, 2022 | -88,052.00 |
| Mar 31, 2022 | -1.47 Mn |
| Dec 31, 2021 | -5.58 Mn |
| Sep 30, 2021 | -1.51 Mn |